and thiazolidine optionally substituted with hydroxy, oxo, mercapto, thio, alkyl or alkanoyl.

5. (original) A compound according to claim 4, wherein said heterocycle is selected from the group consisting of piperidine, piperazine, morpholine, tetrahydrofuran, tetrahydrothiophene, oxazolidine, thiazolidine optionally substituted with hydroxy, oxo, mercapto, thio, alkyl or alkanoyl.

6-9. (cancelled)

10. (original) A compound according to claim 1, wherein X is $-CH_2-NR_6-C(O)-$ wherein the carbonyl $-C(O)-$ portion thereof is covalently bound to Cy and R_6 is H or alkyl.

11. (original) A compound according to claim 1, wherein Y is a carbocycle or heterocycle optionally substituted with hydroxyl or halogen.

12. (original) A compound according to claim 11, wherein Y is furan-2-yl, thiophene-2-yl or phenyl, wherein said phenyl is optionally substituted with halogen or hydroxyl.

13. (cancelled)

14. (currently amended) A compound according to claim ~~13~~, wherein L is ~~$-CH=CH-C(O)-NR_6-CH_2-$, $-CH_2-NR_6-C(O)-$, $-C(O)-N_6-CH_2-$~~, $-CH(OH)-(CH_2)_2-$, $-(CH_2)_2-CH(OH)-$, $-(CH_2)_3-$, ~~$-C(O)-NR_6-CH(R_7)-C(O)-NR_6-$, $-NR_6-C(O)-CH(R_7)-NR_6-C(O)-$, $-CH(OH)-CH_2-$~~

~~O~~ or $-CH(OH)-CF_2-CH_2-$ ~~wherein each R_6 is independently H or alkyl and R_7 is an amino acid side chain~~.

15. (original) A compound according to claim 14, wherein R_1 is H, OH, amino, O-carbocycle or alkoxy optionally substituted with a carbocycle.

16. (original) A compound according to claim 15, wherein R_1 is H or C_{1-4} alkyloxy.

17. (original) A compound according to claim 1, wherein at least one of R_2 and R_3 is halogen and the other is H or halogen.

18. (original) A compound according to claim 17, wherein R_2 and R_3 are both Cl.

19. (original) A compound according to claim 18, wherein R_4 and R_5 are both H.

20. (original) A pharmaceutical composition comprising a compound according to claim 1 with a pharmaceutically acceptable adjuvant, diluent or carrier.

21. (cancelled)

22. (currently amended) A method of treating a disease or condition mediated by LFA-1 binding to an ICAM protein ligand in a mammal comprising administering to said mammal an effective amount of a compound according to claim 1 wherein said disease or condition is arthritis, psoriasis,

organ transplant rejection, asthma, and inflammatory bowel disease.

23. (cancelled)

23. (currently amended) A method of treating ~~inhibiting~~ an inflammatory disease or condition in a mammal comprising administering to said mammal an effective amount of a compound according to claim 1, wherein said disease or condition is arthritis, psoriasis, organ transplant rejection, asthma, and inflammatory bowel disease.

Ex-A

24. (new) The compound of claim 1 having the formula (Id)



(Id)

Cy is a non-aromatic heterocycle optionally substituted with hydroxyl, mercapto, thioalkyl, halogen, oxo, thio, amino, aminoalkyl, amidine, guanidine, nitro, alkyl, alkoxy or acyl;

Y is a carbocycle or heterocycle optionally substituted with hydroxyl, mercapto, halogen, oxo, thio, thioalkyl, amino, aminoalkyl, carbocycle or heterocycle ring, hydrocarbon, a halo-substituted hydrocarbon, amino, amidine, guanidine, cyano, nitro, alkoxy or acyl;